Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>Low‐dose CT screening allows early lung cancer detection, but is affected by frequent false positive results, inter/intra observer variation and uncertain diagnoses of lung nodules. Radiomics‐based models have recently been introduced to overcome these issues, but limitations in demonstrating their generalizability on independent datasets are slowing their introduction to clinic. The aim of this study is to evaluate two radiomics‐based models to classify malignant pulmonary nodules in low‐dose CT screening, and to externally validate them on an independent cohort. The effect of a radiomics‐features harmonization technique is also investigated to evaluate its impact on the classification of lung nodules from a multicenter data.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Pulmonary nodules from two independent cohorts were considered in this study; the first cohort (110 subjects, 113 nodules) was used to train prediction models, and the second cohort (72 nodules) to externally validate them. Literature‐based radiomics features were extracted and, after feature selection, used as predictive variables in models for malignancy identification. An in‐house prediction model based on artificial neural network (ANN) was implemented and evaluated, along with an alternative model from the literature, based on a support vector machine (SVM) classifier coupled with a least absolute shrinkage and selection operator (LASSO). External validation was performed on the second cohort to evaluate models' generalization ability. Additionally, the impact of the Combat harmonization method was investigated to compensate for multicenter datasets variabilities. A new training of the models based on harmonized features was performed on the first cohort, then tested separately on the harmonized and no‐harmonized features of the second cohort.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Preliminary results showed a good accuracy of the investigated models in distinguishing benign from malignant pulmonary nodules with both sets of radiomics features (i.e. no‐harmonized and harmonized). The performance of the models, quantified in terms of Area Under the Curve (AUC), was >0.89 in the training set and >0.82 in the external‐validation set for all the investigated scenarios, outperforming the clinical standard (AUC of 0.76). Slightly higher performance was observed for the SVM‐LASSO model than the ANN in the external dataset, although they did not result significantly different. For both harmonized and no‐harmonized features, no statistical difference was found between Receiver Operating Characteristic (ROC) curves related to training and test set for both models.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Although no significant improvements were observed when applying the Combat harmonization method, both in‐house and literature‐based models were able to classify lung nodules with good generalization to an independent dataset, thus showing their potential as tools for clinical decision‐making in lung cancer screening.</p></section>

Combining low-dose CT-based radiomics and metabolomics for early lung cancer screening support

Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies

Clinical Validation of Metabolite Markers for Early Lung Cancer Detection

Early lung cancer diagnostic biomarker discovery by machine learning methods

Radiomics analysis to predict pulmonary nodule malignancy using machine learning approaches

High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis

Integrated Models of Blood Protein and Metabolite Enhance the Diagnostic Accuracy for Non-Small Cell Lung Cancer

Molecular biomarkers in early stage lung cancer

External validation of radiomics‐based predictive models in low‐dose CT screening for early lung cancer diagnosis

Towards radiologist-level cancer risk assessment in CT lung screening using deep learning

Non-invasive Decision Support for Clinical Treatment of Non-Small Cell Lung Cancer Using a Multiscale Radiomics Approach.

Combining Metabolomics and Machine Learning to Identify Diagnostic and Prognostic Biomarkers in Patients with Non-Small Cell Lung Cancer Pre- and Post-Radiation Therapy

Combining MALDI-MS with machine learning for metabolomic characterization of lung cancer patient sera

Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data

Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer

Deep Learning Empowers Lung Cancer Screening Based on Mobile Low-Dose Computed Tomography in Resource-Constrained Sites

Lung cancer screening with low-dose CT scans using a deep learning approach

Development and Validation of a Screening Model for Lung Cancer Using Machine Learning: A Large-Scale, Multi-Center Study of Biomarkers in Breath

Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction

Radiomics and artificial intelligence in lung cancer screening

Blood biomarker-aided cancer discrimination of screen-detected small lung nodule: The Cancer Signature Ensemble